Comparison of T cell response to vaccination in rheumatic patients treated with Janus kinase inhibitors and TNF inhibitors
Abstract Background Janus kinase inhibitors (JAKi) represent a well-established therapeutic option for the treatment of autoimmune diseases. However, there is a paucity of evidence regarding their impact on de novo immune responses to vaccinations. T cells may confer long-lasting immunity and cross-...
Saved in:
| Main Authors: | Sebastian Hüper, Florian Eisele, Johannes Duell, Marc Schmalzing, Lea Nagler, Patrick Pascal Strunz, Matthias Froehlich, Jan Portegys, Michael Gernert |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Rheumatology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41927-025-00542-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review
by: Olimpia Wiciun, et al.
Published: (2025-05-01) -
Response to primary canine core vaccination in 10-month-old seronegative dogs treated with three times the recommended therapeutic dose of Ilunocitinib tablets (Zenrelia™)
by: Genevieve M. Fent, et al.
Published: (2025-07-01) -
Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib
by: Luo Y, et al.
Published: (2025-05-01) -
Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01) -
Upadacitinib for Treatment-Resistant Urticarial Vasculitis: A Case Study and Therapeutic Insight
by: Francesca Falcinelli, et al.
Published: (2025-04-01)